Form 4: CytomX Therapeutics General Counsel Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Lloyd A. Rowland, General Counsel of CytomX Therapeutics, sold 10,203 shares of common stock to satisfy tax obligations related to vesting restricted stock units.
Summary
- On March 18, 2025, Lloyd A. Rowland, General Counsel of CytomX Therapeutics, sold 10,203 shares of common stock.
- The shares were sold at a price of $0.599 per share.
- The sale was executed to cover tax or other government withholding obligations related to the vesting of restricted stock units (RSUs).
- Following the transaction, Rowland directly owns 120,594 shares, which includes 30,624 RSUs.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations, which is a common practice among company executives.
Industry Context
Sales of shares by company insiders are common and often related to compensation and tax planning. It's important to consider the context of these sales, such as the reason for the sale and the overall holdings of the insider.
Stakeholder Impact
- The sale of shares by a company insider could have a minor negative impact on shareholder sentiment, but is unlikely to have a significant long-term effect.
Key Dates
| Date | Description |
|---|---|
| 03/18/2025 | Date of the transaction (sale of shares) |
| 03/20/2025 | Date of signature on the Form 4 filing |
Keywords
CytomX Therapeutics, Lloyd A. Rowland, Form 4, Share Sale, Restricted Stock Units, Tax Obligations, CTMX, General Counsel
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.